287 related articles for article (PubMed ID: 35970234)
1. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis.
Im JHB; Jin YP; Chow R; Dharia RS; Yan P
Surv Ophthalmol; 2022; 67(6):1593-1602. PubMed ID: 35970234
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M
Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
5. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
[TBL] [Abstract][Full Text] [Related]
6. Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study.
Naravane AV; Mundae R; Zhou Y; Santilli C; van Kuijk FJGM; Nazari H; Yamanuha J; Emerson GG; Koozekanani DD; Montezuma SR
PLoS One; 2021; 16(2):e0247161. PubMed ID: 33596257
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
8. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
[TBL] [Abstract][Full Text] [Related]
9. The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown.
Bulut MN; Sönmez HS; Gökçe G; Ağaçkesen A; Bulut K; Hacısalihoğlu A; Arsan A; Şimşek Ş
Photodiagnosis Photodyn Ther; 2021 Sep; 35():102449. PubMed ID: 34314862
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
Ou WC; Brown DM; Payne JF; Wykoff CC
Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
[TBL] [Abstract][Full Text] [Related]
12. Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Tsao YC; Chen TY; Wang LA; Lee CC; Lee WA; Hsu SM; Lai CC; Shao SC; Hung JH; Lai EC
BioDrugs; 2023 Nov; 37(6):843-854. PubMed ID: 37676536
[TBL] [Abstract][Full Text] [Related]
13. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
15. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
16. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
Ciulla T; Pollack JS; Williams DF
Br J Ophthalmol; 2021 Dec; 105(12):1696-1704. PubMed ID: 33055088
[TBL] [Abstract][Full Text] [Related]
17. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
18. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusions: A Systematic Review and Meta-Analysis.
Spooner K; Hong T; Fraser-Bell S; Chang A
Asia Pac J Ophthalmol (Phila); 2019; 8(3):236-246. PubMed ID: 31132002
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
20. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]